A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00073203|
Recruitment Status : Completed
First Posted : November 19, 2003
Last Update Posted : August 28, 2009
The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder.
Approximately 488 subjects will be involved in the study.
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder||Drug: R228060 Drug: Placebo and Paroxetine||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||488 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 6- Week, Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD)|
|Study Completion Date :||May 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00073203
|United States, New Jersey|
|JJ PRD Research Center|
|Titusville, New Jersey, United States, 08560|